FDA WARNING_LETTER - Insight Pharmaceuticals Corporation

The FDA issued a Warning Letter to Insight Pharmaceuticals, LLC, regarding their drug product, "Auro Earache Relief Ear Drops," based on a review of its labeling and marketing information. The product is deemed misbranded under sections 502 and 503 of the FD&C Act and violates section 301.

The product's labeling, including its name and claims like "Relieves earache pain" and "temporary relief of pain, discomfort, and irritability associated with earaches," establishes it as a drug. Despite being marketed OTC, the FDA classifies it as a prescription drug under section 503(b)(1) because ear pain requires diagnosis and treatment by a physician, and it's not a recognized OTC indication in the final monograph for topical otic drug products (21 C.F.R. § 344).

Consequently, the product is misbranded under section 503(b)(4) for failing to bear the "Rx only" symbol and under section 502(f)(1) for lacking adequate directions for use, as the indication is not appropriate for OTC use. Furthermore, it is misbranded under section 502(a) because its labeling is false or misleading by representing the product as suitable for OTC treatment of a condition that requires professional diagnosis.

The FDA clarified that homeopathic drugs are subject to the same regulatory requirements as other drugs and must comply with section 5